98 related articles for article (PubMed ID: 21766661)
1. [Basic concept for the treatment of metabolic syndrome].
Katayama S
Nihon Rinsho; 2011 Jan; 69 Suppl 1():566-70. PubMed ID: 21766661
[No Abstract] [Full Text] [Related]
2. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Schindler C
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):7-26. PubMed ID: 19124392
[TBL] [Abstract][Full Text] [Related]
3. Cardiology patient page. The metabolic syndrome.
Lennie TA
Circulation; 2006 Oct; 114(15):e528-9. PubMed ID: 17030691
[No Abstract] [Full Text] [Related]
4. [Drug treatment of insulin resistance].
Tenoutasse S
Rev Med Brux; 2009; 30(2):126-8. PubMed ID: 19517913
[No Abstract] [Full Text] [Related]
5. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
Naruszewicz M
Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
[No Abstract] [Full Text] [Related]
6. [Metabolic syndrome].
Hanada H; Okumura K
Nihon Rinsho; 2007 Sep; Suppl 5 Pt 2():7-11. PubMed ID: 17952966
[No Abstract] [Full Text] [Related]
7. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
8. Identifying patients with metabolic syndrome.
Krentz AJ
Practitioner; 2009; 253(1720):27-30. PubMed ID: 19715053
[No Abstract] [Full Text] [Related]
9. Reversing the tide of metabolic syndrome.
Dumas MA
Nurs Manage; 2003 Jun; 34 Suppl Guide():1-5. PubMed ID: 12867772
[TBL] [Abstract][Full Text] [Related]
10. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
Attallah H; Friedlander AL; Hoffman AR
Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
[TBL] [Abstract][Full Text] [Related]
11. The metabolic syndrome: a gathering challenge in a time of abundance.
Bricker LA; Greydanus DE
Adolesc Med State Art Rev; 2008 Dec; 19(3):475-97, ix. PubMed ID: 19227387
[TBL] [Abstract][Full Text] [Related]
12. Effective treatments for insulin resistance: trim the fat and douse the fire.
Evans JL; Youngren JF; Goldfine ID
Trends Endocrinol Metab; 2004 Nov; 15(9):425-31. PubMed ID: 15519889
[TBL] [Abstract][Full Text] [Related]
13. [Discharge letter with therapeutic recommendations: you have to sort out!].
Stiefelhagen P
MMW Fortschr Med; 2010 Mar; 152(10):31-2. PubMed ID: 20380229
[No Abstract] [Full Text] [Related]
14. Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome.
Godoy-Matos AF; Bahia LR; Domingues RC; Tambascia M; Geloneze B; Kraemer-Aguiar LG; Bouskela E
Diabet Med; 2010 Jan; 27(1):23-9. PubMed ID: 20121885
[TBL] [Abstract][Full Text] [Related]
15. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
16. [Integrated drug therapy of the metabolic syndrome].
Julius U; Hanefeld M
Internist (Berl); 1996 Jul; 37(7):722-30. PubMed ID: 8766266
[No Abstract] [Full Text] [Related]
17. Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome.
Iba A; Kohjimoto Y; Mori T; Kuramoto T; Nishizawa S; Fujii R; Nanpo Y; Matsumura N; Shintani Y; Inagaki T; Hara I
BJU Int; 2010 Nov; 106(10):1550-4. PubMed ID: 20184575
[TBL] [Abstract][Full Text] [Related]
18. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome.
Lord J; Thomas R; Fox B; Acharya U; Wilkin T
BJOG; 2006 Oct; 113(10):1203-9. PubMed ID: 16753044
[TBL] [Abstract][Full Text] [Related]
19. Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?
Krentz AJ; Clough G; Byrne CD
J Vasc Res; 2009; 46(6):515-26. PubMed ID: 19571572
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
Yuen KC; Dunger DB
Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
